From Halsted to prevention and beyond: Advances in the management of breast cancer during the twentieth century

European Journal of Cancer

Volumn 35, Issue 14, 1999, Pages 1963-1973

  Fisher, B ^a  

^a NSABP Foundation Inc   (United States)

Author keywords

Breast cancer; Chemotherapy; Clinical trials; History; Intraductal carcinoma; Invasive; Non invasive; Prevention; Surgery; Tamoxifen; Twentieth century

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTRADIOL; ESTROGEN RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARCINOMA IN SITU; CELL KINETICS; FOLLOW UP; HUMAN; INVASIVE CARCINOMA; MAMMOGRAPHY; MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0033398357     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00217-8     Document Type: Article

References (66)

1. Halsted W.S. A clinical and histological study of certain adenocarcinoma of the breast. and a brief consideration of the supraclavicular operation and of the results of operation for cancer of the breast from 1889 to 1898 at the Johns Hopkins Hospital Ann. Surg. 28:1898;557.
2. Halsted W.S. The results of radical operations for the cure of carcinoma of the breast. Ann. Surg. 46:1907;1.
3. Grubbé E.H. X-ray Treatment, Its Origin, Birth, and Early History. 1949;Bruce, St Paul, Minnesota. 51.
4. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896, 2, 104 and 162.
5. Fisher B. The surgical dilemma in the primary therapy of invasive breast cancer: a critical appraisal. Curr Probl Surg 1970, October, 3-53.
6. Bernard C. Introduction à l'Étude de la Médicine Experimentale. Paris, 1865.
7. Root-Bernstein R.S. Discovering. 1989;Harvard University Press, Cambridge, Massachusetts. 501.
8. Streptomycin treatment of pulmonary tuberculosis. Br. Med. J. 2:1948;769.
9. Thomas L. Quoted in: Redmond C, Fisher B. Design of the controlled clinical trial. In Pilch YH, Das Gupta T, eds. Surgical Oncology. New York, McGraw Hill, 1994, 254-272.
10. The effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. an overview of 61 randomized trials among 28 896 women N. Engl. J. Med. 319:1988;1681-1692.
11. Early Breast Cancer Trialists' Collaborative Group. A systemic overview of all available randomized trials in early breast cancer of adjuvant endocrine and cytotoxic therapy. In Treatment of Early Breast Cancer, Volume 1: Worldwide Evidence 1985-1990. Oxford, Oxford University Press, 1990, 207.
12. DeSombre E.R. Estrogens, receptors and cancer. the scientific contributions of Elwood Jensen Prog. Clin. Biol. Res. 322:1990;17-29.
13. Jordan V.C. The development of tamoxifen for breast cancer therapy. a tribute to the late Arthur L. Walpole Breast Cancer Res. Treat. 11:1988;197-209.
14. Gold R.H. The evolution of mammography. Radiol. Clin. North Am. 30:1992;1-19.
15. Holleb A.I. Sixth annual Wendell G. Scott memorial lecture. Cancer. 43:1979;2547-2552.
16. Kuhn T.S. The Structure of Scientific Revolutions. 2nd ed. 1970;University of Chicago Press, Chicago.
17. Fisher B. The evolution of paradigms for the management of breast cancer. a personal perspective Cancer Res. 52:1992;2371-2383.
18. Fisher B, Fisher ER. Biologic aspects of cancer-cell spread. In Proceedings of the Fifth National Cancer Conference. Philadelphia, Pennsylvania, Lippincott, 1965, 105-122.
19. Fisher B., Fisher E.R. The biology of metastasis. Davis J.H. Current Concepts in Surgery. 1965;321-351 McGraw Hill, New York.
20. Fisher E.R., Fisher B. Host-tumor relationship in the development and growth of hepatic metastases. Wissler R.W., Dao T.L., Wood Jr S. Endogenous Factors Influencing Host-Tumor Balance. 1967;149-166 University of Chicago Press, Chicago.
21. Fisher B., Fisher E.R. Metastases of cancer cells. Busch H. Methods in Cancer Research. 1967;243-286 Academic Press, New York.
22. Fisher B. Laboratory and clinical research in breast cancer - a personal adventure. the David A. Karnofsky Memorial Lecture Cancer Res. 40:1980;3863-3874.
23. Fisher B. The interdependence of laboratory and clinical research in the study of metastases. In Nicolson GL, Miles L, eds. Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects. New York, Raven Press, 1984, 27-46.
24. Fisher B., Redmond C., Fisher E.R.et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N. Engl. J. Med. 312:1985;674-681.
25. National Surgical Adjuvant Breast and Bowel Project (NSABP). Progress Report, July 1998, 17-23.
26. Fisher B., Anderson S., Redmond C., Wolmark N., Wickerham L., Cronin W. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N. Engl. J. Med. 333:1995;1456-1461.
27. National Surgical Adjuvant Breast and Bowel Project (NSABP). Progress Report, July 1998, 31-39.
28. Veronesi U., Saccozzi R., Del Vecchio M.et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N. Engl. J. Med. 305:1981;6-11.
29. Fisher E.R., Turnbull R.B. Jr. Cytologic demonstration and significance of tumor cells in the mesenteric venous blood in patients with colorectal carcinoma. Surg. Gynecol. Obstet. 100:1955;102-108.
30. Shapiro D.M., Fugmann R.A. A role of chemotherapy as an adjunct to surgery. Cancer Res. 17:1957;1098-1101.
31. Fisher B., Slack N., Katrych D., Wolmark N. Ten-year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg. Gynecol. Obstet. 140:1975;528-534.
32. Skipper H.E. Kinetics of mammary tumor cell growth and implications for therapy. Cancer. 28:1971;1479-1499.
33. Fisher B., Carbone P., Economou S.G.et al. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. a report of early findings N. Engl. J. Med. 292:1975;117-122.
34. Bonadonna G., Brusamolino E., Valagussa P.et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 294:1976;405-410.
35. Adam H.K. Pharmacokinetic studies with Nolvadex. Rev. Endocr-Rel. Cancer. 9(Suppl.):1981;131-143.
36. Wakeling A.E., Valcaccia B., Newboult E., Green L.R. Non-steroidal anti-oestrogens - receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J. Steroid Biochem. 20:1984;111-120.
37. Terenius L. Effect of anti-oestrogens on initiation of mammary cancer in the female rat. Eur. J. Cancer. 7:1971;65-70.
38. Jordan V.C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer. 12:1976;419-424.
39. Jordan V.C., Allen K.E. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur. J. Cancer. 16:1980;239-251.
40. Heuson J.C. Current overview of EORTC clinical trials with tamoxifen. Cancer Treat. Rep. 60:1976;1463-1466.
41. Mouridsen H., Palshof T., Patterson J., Battersby L. Tamoxifen in advanced breast cancer. Cancer Treat. Rev. 5:1978;131-141.
42. Legha S.S., Buzdar A.U., Hortobagyi G.N., Wiseman C., Benjamin R.S., Blumenschein G.R. Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. J. Am. Med. Assoc. 242:1979;49-52.
43. Margreiter R., Wiegele J. Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer. Breast Cancer Res. Treat. 4:1984;45-48.
44. Baum M., Brinkley D.M., Dossett J.A.et al. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Lancet. 1:1983;257-260.
45. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet 1985, 1, 836-840.
46. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987, 2, 171-175.
47. Fisher B., Redmond C., Brown A.et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer. 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial J. Clin. Oncol. 4:1986;459-471.
48. Fisher B., Redmond C., Legault-Poisson S.et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen. results from NSABP B-16 J. Clin. Oncol. 8:1990;1005-1018.
49. Fisher B., Costantino J., Redmond C.et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320:1989;479-484.
50. Fisher B., Dignam J., Bryant J.et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst. 88:1996;1529-1542.
51. Fisher B., Dignam J., Wolmark N.et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl. Cancer Inst. 89:1997;1673-1682.
52. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 33 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992, 339, 1-15, 71-85.
53. Adjuvant chemotherapy for breast cancer. J Am Med Assoc 1985, 254, 3461-3463.
54. NIH Consensus Development Conference, 18-21 June 1990. Vol. 8, number 6, 1-17.
55. Fisher B., Anderson S., Wickerham D.L.et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer. findings from National Surgical Adjuvant Breast and Bowel Project B-22 J. Clin. Oncol. 15:1997;1858-1869.
56. Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999, 17, 1-15.
57. Fisher B., Brown A., Mamounas E.et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer. findings from National Surgical Adjuvant Breast and Bowel Project B-18 J. Clin. Oncol. 15:1997;2483-2493.
58. Fisher B., Bryant J., Wolmark N.et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16:1998;2672-2685.
59. Fisher B., Mamounas E.P. Preoperative chemotherapy. a model for studying the biology and therapy of primary breast cancer J. Clin. Oncol. 13:1995;537-540.
60. Fisher B., Redmond C. New perspective on cancer of the contralateral breast. a marker for assessing tamoxifen as a preventive agent J. Natl. Cancer Inst. 83:1991;1278-1280.
61. Fisher B., Costantino J.P., Wickerham D.L.et al. Tamoxifen for prevention of breast cancer. report of the National Surgical Adjuvant Breast and Bowel Project P-1 study J. Natl. Cancer Inst. 90:1998;1371-1388.
62. Fisher B. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. a reflective commentary J. Clin. Oncol. 17:1999;1632-1639.
63. Fisher B., Costantino J., Redmond C.et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N. Engl. J. Med. 328:1993;1581-1586.
64. Fisher B., Dignam J., Wolmark N.et al. Tamoxifen in treatment of intraductal breast cancer. National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial Lancet. 353:1999;1993-2000.
65. Fisher B. A personal perspective about the future of breast cancer research and treatment. Hortobagyi G.N., Khayat D. Progress in Anti-cancer Chemotherapy. 1999;34-53 Springer, Paris.
66. Fisher B., Costantino J., Redmond C.et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320:1989;479-484.